Cargando…

Correction to: Dapagliflozin: A Review in Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	Dhillon, Sohita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943399/ https://www.ncbi.nlm.nih.gov/pubmed/31773635 http://dx.doi.org/10.1007/s40265-019-01239-1

Ejemplares similares

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

Correction to: Lonafarnib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Correction to: Lazertinib: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Correction to: Zavegepant: First Approval
por: Dhillon, Sohita
Publicado: (2023)

Correction to: Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Correction to: Moxetumomab Pasudotox: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Correction: Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats
por: Yang, Xudong, et al.
Publicado: (2023)

Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
por: Bailey, Clifford J, et al.
Publicado: (2013)

Correction: Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
por: Chang, Yoon-Kyung, et al.
Publicado: (2016)

Correction to: Effect of dapagliflozin on COVID-19 infection and risk of hospitalization
Publicado: (2023)

Correction to: Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin
por: Hayashi, Toshiyuki, et al.
Publicado: (2017)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
por: Saeed, Mujahid A, et al.
Publicado: (2014)

Correction to: Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
por: Shibata, Ryo, et al.
Publicado: (2022)

Eculizumab: A Review in Generalized Myasthenia Gravis
por: Dhillon, Sohita
Publicado: (2018)

Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
por: Dhillon, Sohita
Publicado: (2018)

Author Correction: Comparative study of Dapagliflozin versus Glimepiride effect on insulin regulated aminopeptidase (IRAP) and interleukin-34 (IL-34) in patient with type 2 diabetes mellitus
por: Zekry, Rania, et al.
Publicado: (2023)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
por: Chao, Edward C
Publicado: (2012)

Ertugliflozin for type 2 diabetes [Correction]
Publicado: (2019)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes
por: Bletsa, Evdoxia, et al.
Publicado: (2021)

Correction to: Sex differences in type 2 diabetes
por: Kautzky-Willer, Alexandra, et al.
Publicado: (2023)

Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU
por: Dhillon, Sohita
Publicado: (2019)

Correction: Incidence of Type 2 Diabetes in Japan: A Systematic Review and Meta-Analysis
por: Goto, Atsushi, et al.
Publicado: (2013)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Moxetumomab Pasudotox: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p3k6ukvfnh40ckh8ootifveuns